Symbols

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

NCEL

NewcelX·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NCEL

Newcelx Ltd.

A clinical-stage biopharmaceutical company that developing innovative therapies for rare and complex central nervous system disorders

Industry

Chemical and pharmaceutical

Established Date

06/10/2015

Listing Date

01/29/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.newcelx.com

Security Type

Common stock

Office address

Hohstrasse 1 8302 Kloten Switzerland

Business

Develops drug therapies for CNS disorders.

Introduction

NewcelX Ltd. was established on June 10, 2015. The company is an innovative biopharmaceutical company dedicated to the discovery and development of life-enhancing drug therapies for rare central nervous system diseases. NewcelX is focused on developing transformative stem cell-derived therapies for the treatment of type 1 diabetes. Based on the proven human pluripotent stem cell (hPSC) platform, the company's lead project aims to restore functional insulin secretion through scalable, off-the-shelf cell replacement therapies. NewcelX is advancing a comprehensive treatment program for type 1 diabetes that integrates cell therapy, immune protection and translational science to address critical unmet medical needs.

Company Financials

EPS

NCEL has released its 2021 Q1 earnings. EPS was reported at -0.41, versus the expected 0, missing expectations. The chart below visualizes how NCEL has performed over recent quarters, highlighting trends in earnings surprises.